secwatch.observer — SEC 8-K summary
======================================

Issuer:     AMGEN INC (AMGN)
CIK:        0000318154
Form:       8-K
Filed at:   2023-12-14T23:59:59+00:00
Accession:  0001193125-23-295027
Event type: leadership
Sentiment:  positive
Materiality: 0.65
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Amgen names James Bradner as EVP R&D/CSO; David Reese transitions to CTO
------------------------------------------------------------------------

- James Bradner, formerly President of Novartis Institutes for BioMedical Research, joins as EVP R&D and CSO effective Dec 18, 2023.
- David M. Reese moves from EVP R&D to newly created EVP and Chief Technology Officer role effective Dec 18, 2023.
- Both executives report to Chairman and CEO Robert A. Bradway.
- Reese will lead acceleration of AI and technology across Amgen; he was key architect of Amgen's AI initiatives.
- Announcement made Dec 14, 2023; appointments underscore Amgen's push to converge biotech and tech.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/318154/000119312523295027/0001193125-23-295027-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/318154/000119312523295027/d598661d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-295027

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer